Literature DB >> 1563453

Long-term results of corticosteroid therapy in patients with myasthenia gravis.

A Evoli1, A P Batocchi, M T Palmisani, M Lo Monaco, P Tonali.   

Abstract

We studied the long-term outcome of prednisone therapy in 104 patients with myasthenia gravis (MG). At the end of the follow-up period, good therapeutic results were recorded in 85 patients (81.7%), poor results in 13 (12.5%) and no significant change of MG status in 6 (5.8%). We found a correlation between the duration of treatment and the incidence of steroid side effects. The presence of thymoma and severe forms of MG were associated with relapsing disease requiring prolonged corticosteroid regimens. The age at the start of therapy did not influence significantly the response to treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563453     DOI: 10.1159/000116785

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  23 in total

1.  Intercommunication between the neuroendocrine and immune systems: focus on myasthenia gravis.

Authors:  Jacqueline Mays; Cherié L Butts
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

Review 2.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

4.  Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.

Authors:  Ahmad R Abuzinadah; Duaa Jabari; Omar Jawdat; Mamatha Pasnoor; Melanie Glenn; Laura Herbelin; April L McVey; Richard J Barohn; Mazen M Dimachkie
Journal:  J Clin Neuromuscul Dis       Date:  2018-12

5.  Minimal manifestation status and prednisone withdrawal in the MGTX trial.

Authors:  Ikjae Lee; Hui-Chien Kuo; Inmaculada B Aban; Gary R Cutter; Tarrant McPherson; Henry J Kaminski; Jon Sussman; Philipp Ströbel; Joel Oger; Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Marcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Jan J G Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Greg Minisman; Joshua R Sonett; Gil I Wolfe
Journal:  Neurology       Date:  2020-07-01       Impact factor: 9.910

Review 6.  A practical guide to the recognition and management of myasthenia gravis.

Authors:  A Evoli; A P Batocchi; P Tonali
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

7.  Immunoadsorption plasmapheresis for severe generalised myasthenia gravis.

Authors:  M Ichikawa; C S Koh; Y Hata; M Tohyama; T Tsuno; A Komiyama
Journal:  Arch Dis Child       Date:  1993-08       Impact factor: 3.791

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 9.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

10.  Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors.

Authors:  Ahmad R Abuzinadah; Mohammed H Alanazy; Nadeem S Butt; Richard J Barohn; Mazen M Dimachkie
Journal:  Eur Neurol       Date:  2020-12-15       Impact factor: 1.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.